Insider Selling: Cooper Companies Inc (NYSE:COO) Director Sells 355 Shares of Stock

Share on StockTwits

Cooper Companies Inc (NYSE:COO) Director Gary S. Petersmeyer sold 355 shares of the stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $323.92, for a total transaction of $114,991.60. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Shares of Cooper Companies stock traded up $7.32 on Wednesday, hitting $331.51. The company had a trading volume of 207,248 shares, compared to its average volume of 343,541. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.21 and a quick ratio of 0.68. The stock has a market capitalization of $16.05 billion, a PE ratio of 28.83, a price-to-earnings-growth ratio of 2.47 and a beta of 0.78. Cooper Companies Inc has a 52 week low of $228.65 and a 52 week high of $332.34.

Cooper Companies (NYSE:COO) last posted its quarterly earnings data on Thursday, May 30th. The medical device company reported $2.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.76 by $0.18. The business had revenue of $654.30 million during the quarter, compared to analysts’ expectations of $655.00 million. Cooper Companies had a net margin of 16.46% and a return on equity of 17.25%. The business’s revenue was up 3.6% on a year-over-year basis. During the same period last year, the firm posted $2.86 earnings per share. On average, analysts forecast that Cooper Companies Inc will post 12.24 earnings per share for the current fiscal year.

Several research firms recently weighed in on COO. Zacks Investment Research upgraded shares of Cooper Companies from a “hold” rating to a “buy” rating and set a $336.00 price objective on the stock in a research note on Friday, June 7th. Wells Fargo & Co upped their target price on shares of Cooper Companies from $325.00 to $356.00 and gave the stock an “outperform” rating in a research report on Monday, June 10th. Northcoast Research restated a “buy” rating and issued a $340.00 target price (up previously from $331.00) on shares of Cooper Companies in a research report on Monday, June 3rd. Raymond James upped their target price on shares of Cooper Companies from $300.00 to $325.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 6th. Finally, BMO Capital Markets upped their target price on shares of Cooper Companies from $306.00 to $320.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the stock. Cooper Companies has a consensus rating of “Buy” and a consensus target price of $315.36.

Several institutional investors have recently bought and sold shares of COO. Norges Bank bought a new position in shares of Cooper Companies in the fourth quarter valued at approximately $117,156,000. Veritas Asset Management LLP boosted its holdings in Cooper Companies by 77.8% during the first quarter. Veritas Asset Management LLP now owns 981,302 shares of the medical device company’s stock worth $290,632,000 after buying an additional 429,340 shares in the last quarter. BlackRock Inc. boosted its holdings in Cooper Companies by 7.1% during the fourth quarter. BlackRock Inc. now owns 3,732,729 shares of the medical device company’s stock worth $949,981,000 after buying an additional 246,088 shares in the last quarter. Public Employees Retirement Association of Colorado boosted its holdings in Cooper Companies by 481.9% during the fourth quarter. Public Employees Retirement Association of Colorado now owns 196,798 shares of the medical device company’s stock worth $50,085,000 after buying an additional 162,980 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its holdings in Cooper Companies by 4.1% during the first quarter. Janus Henderson Group PLC now owns 2,834,318 shares of the medical device company’s stock worth $839,449,000 after buying an additional 112,906 shares in the last quarter. Institutional investors and hedge funds own 95.96% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Cooper Companies Inc (NYSE:COO) Director Sells 355 Shares of Stock” was first reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/4380006/insider-selling-cooper-companies-inc-nysecoo-director-sells-355-shares-of-stock.html.

Cooper Companies Company Profile

The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.

Recommended Story: Why is momentum important to successful trading?

Insider Buying and Selling by Quarter for Cooper Companies (NYSE:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

MKM Partners Lowers ADTRAN  Price Target to $17.00
MKM Partners Lowers ADTRAN Price Target to $17.00
Apple  PT Raised to $180.00 at Nomura
Apple PT Raised to $180.00 at Nomura
Advaxis  Lowered to “Hold” at ValuEngine
Advaxis Lowered to “Hold” at ValuEngine
Zacks Investment Research Upgrades Atlas Air Worldwide  to “Hold”
Zacks Investment Research Upgrades Atlas Air Worldwide to “Hold”
Apple  Raised to “Outperform” at Raymond James
Apple Raised to “Outperform” at Raymond James
Zacks Investment Research Lowers Agilysys  to Hold
Zacks Investment Research Lowers Agilysys to Hold


© 2006-2019 Ticker Report